The rhomboid 5 homolog 2 (Rhbdf2) gene encodes an inactive rhomboid (iRhom) protease, iRhom2, one of a family of enzymes containing a long cytosolic N terminus and a dormant peptidase domain of unknown function. iRhom2 has been implicated in epithelial regeneration and cancer growth through constitutive activation of epidermal growth factor receptor (EGFR) signaling. However, little is known about the physiological substrates for iRhom2 or the molecular mechanisms underlying these functions. We show that iRhom2 is a short-lived protein whose stability can be increased by select mutations in the N-terminal domain. In turn, these stable variants function to augment the secretion of EGF family ligands, including amphiregulin, independent of metalloprotease a disintegrin and metalloproteinase 17 (ADAM17) activity. In vivo, N-terminal iRhom2 mutations induce accelerated wound healing as well as accelerated tumorigenesis, but they do not drive spontaneous tumor development. This work underscores the physiological prominence of iRhom2 in controlling EGFR signaling events involved in wound healing and neoplastic growth, and yields insight into the function of key iRhom2 domains.
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curly bare | ERAD | tylosis | epithelial cancer | pseudoenzyme I nactive rhomboids (iRhoms) are highly conserved but proteolytically inactive intramembrane proteins (1) . iRhoms are characterized by a long cytosolic N-terminal domain, a conserved cysteine-rich iRhom homology domain (IRHD), and a dormant proteolytic site lacking an active-site serine residue within the peptidase domain (1) . Recently, Greenblatt et al. (2) reported that Derlin-1 belongs to the rhomboid family and suggested that a dual role exists for the cytosolic and peptidase domains of this novel rhomboid pseudoprotease. They showed that although the cytosolic domain of Derlin-1 is essential in mammalian cells for clearance of misfolded proteins from the endoplasmic reticulum, the transmembrane domain is required to interact with its substrates (2) , suggesting that these two domains have distinctive functions. The physiological significance of these domains is unclear.
Despite their lack of proteolytic activity, iRhoms participate in a diverse range of functions in a variety of species, including regulation of epidermal growth factor receptor (EGFR) signaling in Drosophila melanogaster (3), survival of human squamous epithelial cancer cells (4, 5) , misfolded protein clearance from endoplasmic reticulum membranes in mammalian cell lines (2) , induction of migration in primary mouse keratinocytes (6) , secretion of soluble TNF-α in mice (7, 8) , and regulation of substrate selectivity of stimulated a disintegrin and metalloproteinase 17 (ADAM17)-mediated metalloprotease shedding in mouse embryonic fibroblasts (MEFs) (6, 9) . Although the physiological targets of iRhoms are largely unknown, mounting literature suggests that EGF-like ligands are potential substrates. For example, studies in D. melanogaster and in mammalian cell lines showed that iRhoms could negatively regulate EGFR signaling by breaking down EGF-like substrates through endoplasmic reticulum-associated degradation (ERAD) (3) .
Recent data also point to a role for iRhoms in EGFR-mediated human neoplastic growth. siRNA-mediated silencing of iRhom1 inhibits tumor growth by inducing apoptosis (4) . Likewise, missense mutations in RHBDF2 (p.I186T, p.P189L, and p.D188N), the gene encoding iRhom2, cause tylosis with human esophageal cancer, which is characterized by palmoplantar and oral hyperkeratosis (10) . Other studies have revealed that iRhom1 promotes the survival of epithelial tumors through EGFR transactivation (5), whereas somatic mutations in iRhom2 are strongly linked to gain of EGFR signaling (11) . Although the mechanisms underlying the pathogenesis of cancer are evolving, these studies further strengthen the link between iRhoms and EGFR signaling.
Rhomboids have been extensively characterized in Drosophila, in which changes in EGFR signaling can be detected by studying the wing phenotype (12, 13) , whereas in mice, such alterations can be analyzed by examining hair follicle development (14) , response to wound healing (15) , and tumorigenesis (16) . Here, we show that a spontaneous deletion within the rhomboid 5 homolog 2 (Rhbdf2) gene in mice underlies the curly-bare (cub) mutation, in which loss of the cytosolic N-terminal domain of iRhom2 causes subsequent effects on hair follicle development, wound healing, and tumorigenesis. We find that iRhom2 is a short-lived protein but that gain-of-function mutations in the N terminus (tylosis) or loss of the N terminus (cub mutation) increase mutant protein stability, leading to metalloproteaseindependent secretion of the EGFR ligand amphiregulin (AREG). Using a genetic modifier of the cub phenotype (Mcub), we demonstrate that AREG is a physiological target of iRhom2. We also identify key amino acids in the peptidase domain of iRhom2 that are necessary for AREG secretion, suggesting that the peptidase domain of this pseudoenzyme might be functional de-
Significance
Epidermal growth factor receptor (EGFR) signal transduction plays a major role in growth, proliferation, and differentiation of mammalian cells. Although inactive rhomboids (iRhoms) are cardinal regulators of EGFR signaling in Drosophila melanogaster, their physiological role in regulating EGFR signaling and their substrates in mammals remain unclear. Here, we show that iRhoms are short-lived proteins, but dominant mutations increase their protein stability and stimulate secretion of specific EGF family ligand amphiregulin independent of metalloprotease activity. This study demonstrates the significance of mammalian iRhoms in regulating an EGFR signaling event that promotes accelerated wound healing and triggers tumorigenesis. Given their ability to regulate EGFR signaling in parallel with metalloproteases, iRhoms can be potential therapeutic targets in impaired wound healing and cancer.
spite lacking a serine residue in the putative active site. This study therefore yields insight into the function of key iRhom domains and establishes a framework for understanding the relationship between iRhoms, EGFR signaling, and the biological processes involved in wound healing and tumorigenesis.
Results
cub Mutation Leads to Hyperactivation of the EGFR Signaling Pathway.
We previously described a recessive mouse mutation named cub, which is characterized by a hairless phenotype (17) . We previously mapped the cub mutation to a locus on distal chromosome (Chr) 11 and mapped a dominant Mcub to a 10-cM interval on Chr 5 (17) . A single copy of the dominant Mcub allele in combination with the cub/cub genotype results in a full, wavy coat rather than the hairless coat of cub/cub mcub/mcub mice (17) . Because of the potential relationship between the hair coat phenotypes and EGFR signaling (18, 19) , we investigated whether the cub/cub mcub/mcub genotype might also be associated with other aspects of altered EGFR signaling, such as cell proliferation and cell migration.
We performed proliferation, cell migration (scratch-wound healing), and immunoblot assays on mouse MEFs isolated from cub/cub mcub/mcub and control ( +/+ mcub/mcub) mice. The cub/cub mcub/mcub MEFs had significantly higher rates of proliferation and migration relative to control MEFs ( Fig. 1 A and B) . These changes were associated with significant increases in the phosphorylation of canonical signal transduction proteins of the EGFR pathway, including, Akt, S6, mTOR, and p38 (Fig. 1C) . Further, we observed a significant reduction in cell-surface EGFR levels in cub/cub mcub/mcub MEFs (Fig. 1C) , indicating internalization and constitutive activation of EGFR signaling (20) (21) (22) .
Because activated EGFR signaling mediates epithelial regeneration (23-25), we examined whether this increase in EGFR signaling corresponds to changes in epithelial proliferation. We conducted wound-healing assays in which we punched 2-mm through-and-through holes into the ears of 6-to 40-wk-old cub mice and monitored the rate of closure over subsequent days ( Fig. 1 D-F) . Within 14 d, cub/cub mcub/mcub mice showed accelerated closure compared with control +/+ mcub/mcub littermates. The + /cub mcub/mcub mice (which have a normal coat) also showed faster healing 14 d postinjury relative to control mice ( Fig. S1 A and B) , suggesting that a single mutant cub allele can trigger increased EGFR signaling, although not at levels high enough to block hair follicle induction (17, 26) . These data strongly indicate that the cub/cub mcub/mcub genotype results in a hyperactive EGFR phenotype.
cub Is a Mutation of the Rhbdf2 Gene, Encoding iRhom2. Next, we examined the iRhom2 gene Rhbdf2 as a candidate for the cub mutation because of its coincident position with the cub mutation on Chr 11 and the established relationship between rhomboid proteases and EGFR-mediated signaling (3, 6) . DNA sequencing of cub/cub mice identified a 12,681-bp deletion in the Rhbdf2 gene, which results in loss of exons 2-6 ( Fig. 2A) . To test whether the deletion produces an aberrant Rhbdf2 transcript, we performed reverse transcriptase (RT) PCR on RNA derived from WT and cub/cub mcub/mcub MEFs using primers designed to amplify exons 2, 5, 12, and 19. As expected from the extent of the genomic deletion, the cub transcript contained exons 12 and 19 but lacked exons 2 and 5 (Fig. 2B) . Further, quantitative RT-PCR (qPCR) on RNA from cub/cub mcub/mcub and +/+ mcub/mcub skin amplified cub transcripts in which exons 2-6 were deleted but the remaining exons were expressed, suggesting that the rest of the cub gene is transcribed in cub mice (Fig. 2C) . The structure of the cub genomic deletion suggests that cub transcripts would result in splicing of exons 1-7. To test this interpretation, we performed qPCR with a probe specifically designed to amplify only transcripts containing exon 1 spliced to exon 7. Using this probe, we detected a PCR product in cub/cub mcub/mcub mice but not in +/+ mcub/mcub mice (Fig. 2D ). These findings confirm that cub is a mutation of the Rhbdf2 gene, and it will henceforth be referred to as Rhbdf2 cub . Given that the normal translation initiation site in exon 3 is missing in Rhbdf2
cub transcripts, we next tested whether these mutant transcripts could produce a mutant iRhom2 protein. Sequence analysis of Rhbdf2 cub DNA revealed that the next in-frame translation initiation site (ATG) was in exon 8, which would result in an ∼63.5-kDa protein. Because we lacked an antibody to iRhom2, we tested whether Rhbdf2 cub transcripts could produce a protein product in vitro by cloning both fulllength WT human RHBDF2 cDNA (HuWt) and a version that mimicked the mutant Rhbdf2 cub transcript (HuCub) into a C-terminal Flag-tagged expression vector. First, using immunoblotting, we determined that the HuWt clone generated an ∼100-kDa protein product, whereas the HuCub mutant construct generated an ∼67-kDa product, consistent with the expected molecular mass of the tagged proteins (Fig. 2E) To examine whether Rhbdf2 cub is a gain-of-function mutation rather than a null mutation, we generated Rhbdf2 KO (Rhbdf2 −/− ) mice using ES cells from the Knockout Mouse Project (KOMP) repository, in which lacZ expression is under control of the endogenous Rhbdf2 promoter (Fig. 3A) . Rhbdf2 promoter-driven lacZ expression was predominantly observed in the epidermis and the inner and outer sheath layers of hair follicles in the skin (Fig.  3B) . However, the wound healing ( Fig. 3C ) and loss-of-hair ( Fig.  3D) We next sought to map the mutation underlying the (Table S1 ), we found that Mcub is a loss-of-function mutation in Areg (Fig. 4A ), a gene that encodes the autocrine keratinocyte growth factor AREG (27) .
Mcub is a T-to-G point mutation that destroys the canonical donor splice site of exon 1 and leads to the exclusive use of an alternative downstream splice site that adds 22 extra nucleotides to the Areg transcript; this addition of extra nucleotides disrupts the coding frame and introduces a premature stop codon (Fig.  S3 ). This mutation will henceforth be referred to as Areg
Mcub
. Notably, the hyperactive EGFR signaling (Fig. S4A ) and the rapid wound closure capability of Rhbdf2 cub/cub mice are significantly reduced (Fig. 4 B and C) , and the loss-of-hair phenotype is prevented when a single copy of the dominant Areg Mcub allele is present (17) . The dominant Areg
Mcub mutation does not confer a normal hair coat to the Rhbdf2 cub/cub mice but, rather, a wavy hair phenotype (17) , suggesting remaining abnormalities in the EGFR pathway (28) .
We next measured serum levels of AREG in Rhbdf2 Btc, Epgn, Ereg, and Hbegf). Compared with controls, we observed a fourfold increase in Areg, and subtle but statistically significant increases in Epgn and Hbegf mRNAs, in Rhbdf2 cub/cub Areg +/+ mice. Also, there was a statistically significant decrease in Btc and Egf transcript levels (Fig. 4F) .
Lastly, to examine whether AREG mediates the hyperactive EGFR phenotype, we silenced Areg expression in Rhbdf2 +/+ and Rhbdf2 cub/cub MEFs (Fig. S4B ) using lentiviral shRNA and performed proliferation assays. Whereas silencing of Areg had a subtle effect on proliferation of Rhbdf2 +/+ MEFs (Fig. S4C) , proliferation rates of Rhbdf2 cub/cub MEFs were significantly reduced (Fig. S4D) . Taken together, these data suggest that enhanced AREG levels mediate the mutant phenotype of the Rhbdf2 cub/cub mice via a gain of EGFR signaling. Our findings are consistent with previous reports showing that exposure to high concentrations of AREG influences hair follicle development (26, 27) and tissue regeneration (30, 31) . Furthermore, our data reveal that the Rhbdf2 cub phenotype is modified by Areg
Mcub expression.
N-terminal-Truncated iRhom2 Induces Substrate-Specific Secretion of EGFR Ligands Independent of ADAM17. Nakagawa et al. (32) found that N-terminal-truncated but not full-length iRhom1 induces heparin-binding (HB) EGF secretion in Drosophila. Moreover, recent evidence suggests that active rhomboid proteases, with short or nonexistent N-terminal domains, cleave membranetethered EGF independent of metalloprotease activity (33) . Thus, we asked whether Rhbdf2 cub , with its short N-terminal domain, could induce secretion of AREG independent of metalloprotease activity. We performed in vitro cleavage assays in the presence or absence of marimastat (MM), a potent broad-spectrum metalloprotease inhibitor that can block both ADAM17-and ADAM10-dependent shedding of substrates (34, 35) . Because of the significant homology between the mouse and human RHBDF2 genes (3, 32, 33, 36), we transfected 293T cells with human AREG either alone or with the HuWt or HuCub RHBDF2 gene (Fig. 5A ) and measured AREG levels in conditioned medium. In the absence of MM, we observed no difference in AREG levels between AREG-expressing and AREG/HuCubcoexpressing cells, whereas coexpression of HuWt and AREG reduced AREG levels by ∼60% (Fig. 5B) . Intriguingly, in the presence of MM, AREG levels were approximately twofold higher in HuCub/AREG-cotransfected cells compared with cells transfected with HuWt and AREG or AREG alone (Fig. 5B) . These data suggest that N-terminal-truncated iRhom2 can enhance AREG secretion, which only becomes apparent when metalloprotease activity is diminished.
iRhom2 has been shown to regulate maturation of ADAM17 and, in turn, ADAM17-dependent shedding (7, 8, 37) . Because Rhbdf2 cub is a gain-of-function mutation rather than a null mutation, there is a possibility that Rhbdf2 cub could enhance ADAM17 activity, and thereby increase AREG secretion. ADAM17 activity can be measured in mice by examining TNF-α secretion after stimulation with bacterial endotoxin LPS (7, 8 found that both LPS-injected Rhbdf2 cub/cub and Rhbdf2 −/− mice had a markedly lower induction of TNF-α relative to LPSinjected Rhbdf2 +/+ mice (Fig. 5C ). These results suggest that ADAM17 activity is significantly attenuated in Rhbdf2 cub/cub and Rhbdf2 −/− , and they also implicate a role for the N-terminal domain of iRhom2 in regulation of ADAM17-dependent TNF-α release. Notably, serum TNF-α levels in LPS-stimulated Rhbdf2 cub/cub mice were not completely abrogated, suggesting that ADAM17 activity is attenuated but not eliminated (38) . The observation that ADAM17 activity is attenuated in Rhbdf2 cub/cub mice explains the nonlethal or noninflammatory cutaneous phenotype in Rhbdf2 −/− and Rhbdf2 cub/cub mice compared with Adam17 −/− mice (39, 40) or with transgenic mice overexpressing AREG (41) . We next sought to assess the protease selectivity of the active rhomboid proteases for other EGF-like substrates, and whether these differed from HuCub. In accordance with a previous study (33), we found that RHBDL2 selectively increased secretion of EGF but not AREG or HB-EGF compared with empty vectortransfected controls (Fig. 5D) . In contrast, HuCub selectively increased secretion of AREG and HB-EGF but not EGF compared with empty vector-transfected cells (Fig. 5 E-G) . These results suggest that the rhomboid peptidase domain confers substrate selectivity. The ability of N-terminal-truncated iRhom1 to induce AREG but not EGF secretion is consistent with this assertion (Fig. S5 A and B) .
To determine how the iRhom2 peptidase domain helps to regulate the secretion of EGF-like substrates, we initially aligned sequences for amino acids of the peptidase domains of human and mouse iRhoms. We found a significant difference in protein sequence homology between the peptidase domains of human iRhom2 and RHBDL2 (Fig. S5C) . By contrast, the peptidase domains of iRhom1 and iRhom2 show 96% homology. Together, these data suggest that the residues that form the active site or play a role in substrate recognition differ significantly between active rhomboids and iRhoms. In addition, we found that deletion of the HuCub peptidase domain significantly diminished AREG secretion compared with native HuCub (Fig. 5G) , suggesting that the peptidase domain is essential for secretion of EGF-like substrates. To identify the critical residues, we performed site-directed mutagenesis such that key residues in the HuCub peptidase domain were mutated to alanines. We found that glutamine-426 and cysteine-C432 in transmembrane domain 4, and histidine-366 and histidine-475 in transmembrane domains 2 and 6, respectively, were critical not only for mediating enhanced secretion of AREG/HB-EGF but also for suppression of EGF (Fig. 5 H and I) . However, mutations in serines S362A, 402A, and 425A; glutamic acid E436A; and glutamine Q439A did not alter AREG secretion (Fig. S5D) . Together, these results suggest that key residues (Fig. 5J and Fig. S5E ) in the peptidase domain of N-terminal-truncated iRhom regulate the secretion of EGF-like substrates independent of metalloprotease activity.
N-Terminal-Truncated iRhom2 Increases Susceptibility to Epithelial
Cancers. Two recent studies indicated that missense mutations in RHBDF2 (p.I186T, p.P189L, and p.D188N) underlie a familial tylosis with esophageal cancer syndrome in families in the United States, United Kingdom, Germany, and Finland (11, 42) . Based on our results on Rhbdf2 cub mutant mice, we predicted that increased AREG secretion due to dominant N-terminal mutations in RHBDF2 might drive these human pathological changes. We first tested this hypothesis in vitro by coexpressing AREG with a HuWt clone containing the human missense mutation (RHBDF2 p.I186T) (11) medium and lower intracellular levels compared with HuWt ( Fig.  6 A and B) . Further, RHBDF2 p.I186T produced AREG levels comparable to those produced by HuCub, suggesting that loss of, or dominant mutations in, the iRhom2 N terminus lead to increased AREG secretion. Additionally, we found that loss of at least one of four critical residues (H, C, Q, and H) in the peptidase domain of the RHBDF2 p.I186T mutant resulted in significantly decreased AREG secretion (Fig. 6C) .
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To determine whether the Rhbdf2 cub allele increases tumor susceptibility, we investigated how its expression would affect adenoma formation in Apc Min/+ mice, a mouse model of human familial adenomatous polyposis. In Apc Min/+ mice, spontaneous loss of one WT Apc allele induces intestinal epithelial adenoma formation and premature death at a median age of 169 d (43) . Notably, Rhbdf2 (Fig. 6D) significantly increased the number of polyps (Fig. 6 F and G) and adenoma size (Fig. 6 F and H) in Apc Min/+ mice, suggesting that the cub mutation increases the growth of epithelial tumors. However, there was no spontaneous incidence of cancer in Rhbdf2 cub/cub mice aged up to 2 y, suggesting that Rhbdf2 cub mutation creates a conducive environment for, but alone does not drive, tumor development.
Loss of the Cytosolic N Terminus or Dominant Mutations in the N
Terminus of the RHBDF2 Gene Increase Its Protein Stability. iRhom2 negatively regulates EGFR signaling by promoting degradation of EGF-like ligands through the proteasomal pathway (3). Moreover, we observed that iRhoms induce secretion of AREG/ HB-EGF when the cytosolic N terminus is lacking (Fig. 5) . Thus, we asked whether gain-of-function mutations in the amino terminus of iRhom2 interfere with proteasomal processing, and thereby increase its stability. We initially examined whether the tylotic RHBDF2 mutant p.I186T has an ability to interact with AREG. We found that similar to HuWt and HuCub, p.I186T forms physical complexes with AREG (Fig. 7A) . We then compared the protein expression levels of HuWt, HuCub, and p. I186T in 293T and COS7 cells by immunocytochemistry and flow cytometry. We observed that HuWt protein expression was significantly lower compared with both HuCub and p.I186T ex- pression ( Fig. 7 B and C) . Further, when we subjected COS7 cells to a cycloheximide (a protein synthesis inhibitor) chase for the indicated times, within 1 h, we observed an ∼50% reduction in immunoreactivity for HuWt compared with either HuCub or the p.I186T (Fig. 7 D and E) . Endoplasmic reticulum-localized rhomboid proteases interact with the ubiquitin proteasome system to promote ERAD (2, 3, 36) . Because iRhom2 participates in ERAD, it is possible that it could be a target of proteasomal degradation. We determined the protein t 1/2 of HuWt and HuCub in the presence of a potent proteasomal inhibitor, MG-132. Expectedly, the protein t 1/2 of HuWt, but not HuCub, was significantly increased (Fig. 7F) , suggesting that the proteasomal degradation of iRhom2 might be affecting its protein stability. We conclude that missense mutations in the amino terminus of iRhom2, similar to the Rhbdf2 cub mutation, increase its stability and contribute to enhanced AREG secretion independent of metalloprotease activity.
Discussion
The EGFR signal transduction pathway plays an essential role in growth, proliferation, and differentiation of mammalian cells. Canonical EGFR ligands, including EGF, AREG, and HB-EGF, exist as proproteins expressed at the cell surface that, to bind EGFRs, must be shed into the extracellular compartment. Different classes of proteases cleave membrane-tethered EGFR proligands to regulate a broad range of biological activities during various stages of development. Here, we report that iRhom2, a member of a family of rhomboid proteases well known as regulators of EGFR signaling in Drosophila, has an ability to regulate EGFR signaling during cutaneous healing and tumor development. We show that iRhom2 is a short-lived protein whose stability can be increased by select mutations in the N-terminal domain. In turn, these stable variants function to enhance AREG secretion independent of metalloprotease activity. We identify an important role for iRhoms in EGFRdependent cell proliferation and wound healing, and show how iRhom2 mutations that increase EGFR signaling, under the right circumstances, can promote cancer development.
N-Terminal and Peptidase Domains Have Separate Functions in
Regulating EGFR Signaling. iRhoms are complex multidomain enzymes that contain a long cytosolic N terminus, a dormant peptidase domain, and a conserved IRHD; the function of these domains remains unknown. Under normal circumstances, iRhoms negatively regulate EGFR signaling by promoting the degradation of EGF-like substrates (3). However, the Rhbdf2 cub mutation is unlikely to be simply a loss-of-function mutation. Rhbdf2 −/− mice failed to recapitulate the Rhbdf2 cub phenotype. In addition, we demonstrate that similar to the Rhbdf2 cub mutation, dominant missense mutations in the N terminus of iRhom2 induce secretion of AREG and HB-EGF in a manner mediated by key amino acids in transmembrane helices 2, 4, and 6 of the peptidase domain. Thus, our results suggest that the cytosolic N terminus of iRhom2 negatively regulates EGFR signaling by suppressing the peptidase domain and, consequently, secretion of AREG/ HB-EGF (Fig. 8) . These findings are consistent with a recent study suggesting that in mammalian cells, whereas the cytosolic domain of Derlin-1, a novel rhomboid pseudoprotease, is essential for clearance of misfolded proteins from the endoplasmic reticulum, the transmembrane domain is required to interact with its substrates (2) . Our findings also reveal more subtle regulatory functions for iRhom2 that are unmasked in N-terminal mutations, such as Rhbdf2 cub .
Instead, the Rhbdf2 cub may be considered a gain-of-function mutation. This conclusion is supported by several pieces of evidence. First, the negative regulatory role of iRhom2 seems to be minimal because Rhbdf2 −/− mice do not present an overt "EGFR hyperactive" phenotype except when combined with the Rhbdf2 cub mutation. Second, cotransfection of HuCub and AREG results in approximately two-to threefold greater levels of AREG compared with transfections of either HuWt and AREG or AREG alone. Third, expression of HuCub induced secretion of membrane-anchored AREG and HB-EGF independent of metalloprotease activity. Fourth, mutant iRhom2 alleles fail to induce secretion of AREG/HB-EGF in the absence of the peptidase domain. Consistent with these observations, transgenic expression of the N-terminal-truncated but not full-length RHBDF1 induces a strong EGFR signaling-related wing phenotype in Drosophila. Additionally, coexpression of truncated RHBDF1 with HB-EGF intensifies the altered wing phenotype in Drosophila, indicating that the truncated iRhom1 might induce secretion of HB-EGF (32), and thereby activate EGFR signaling. These results validate the concept that the cytosolic N terminus contributes to iRhom-elicited ubiquitin processing of EGF family ligands, whereas the iRhom peptidase domain stimulates EGFR signaling when not suppressed by the N terminus.
It has been hypothesized that mutant iRhom2 alleles can enhance maturation of ADAM17 (6), leading to constitutive activation of EGFR signaling. However, we found that mutant iRhom2 alleles induce secretion of AREG and HB-EGF in the presence of saturating concentrations of MM, a potent broadspectrum metalloprotease inhibitor. Maturation of other members of the ADAM family is unaffected by the deficiency of both iRhoms (9) . Moreover, we demonstrate that ADAM17 activity is attenuated in Rhbdf2 cub mice. Thus, we conclude that Rhbdf2 cub and tylotic mutations selectively induce secretion of AREG and HB-EGF independent of metalloprotease activity, and that the transmembrane peptidase domain is necessary for this function.
Hyperactive EGFR Pathway Underlies Accelerated Cutaneous Healing in Rhbdf2 cub Mice. The biology of wound healing is complex. In human adults, wounds are vulnerable to nonfunctional fibrotic tissue formation, whereas wounds occurring during the prenatal period accomplish complete regeneration, resembling scar-free healing in vertebrates, such as axolotls and planarians. Even though the highly orchestrated and rapid events that occur following injury are well documented, the tissue regeneration and remodeling field is still in its infancy. The literature suggests that a strong link exists between rhomboid proteases and cutaneous wound healing. Active rhomboid RHBDL2 has been demonstrated to induce cell proliferation and migration by specifically cleaving EGF, thrombomodulin, and EphrinB3 (33, 44, 45) . In vitro wound-healing assays performed in a human keratinocyte cell line indicate that the expression of RHBDL2 is significantly up-regulated after wounding compared with unwounded controls. Also, increased RHBLD2 expression correlates with increased shedding of membrane-bound thrombomodulin (46) . Although these results suggest that targeting rhomboid proteases might have a therapeutic benefit in impaired cutaneous healing, the physiological substrates of rhomboid proteases are still unclear.
In several mouse models of wound healing, including the "superhealing" Murphy-Roths-Large (MRL/MpJ) strain, studies have shown that excessive inflammation delays healing, whereas rapid reepithelialization and reduced inflammation lead to accelerated and scar-free healing (15, (47) (48) (49) (50) (51) . The ability of Rhbdf2 cub mice to heal wounds rapidly without significant scar formation might be due to a combination of decreased TNF-α secretion due to attenuated ADAM17 activity and rapid reepithelialization induced by augmented AREG production/EGFR hyperactivation. We propose that although decreased TNF-α contributes to a lesser degree of inflammation, increased AREG production facilitates accelerated proliferation and migration of keratinocytes to the wound site in Rhbdf2 cub mice. Moreover, iRhom2 is predominantly expressed in the skin, making it a potential therapeutic target in impaired cutaneous wound healing.
iRhom2-AREG-EGFR Pathway Is Constitutively Active in Some Epithelial
Cancers. Several studies have implicated iRhom mutations in cancer. For example, overexpression of the RHBDF1 gene, which encodes iRhom1, is crucial in sustaining growth signaling in epithelial cancer cells (4, 5) . Significant elevation of RHBDF1 transcript levels is observed in breast cancer clinical specimens. Although iRhom1 suppresses secretion of EGF family ligands and negatively regulates EGFR signaling (3), a recent study suggests that iRhom1 might have additional physiological roles (9) . For instance, it has been implicated in G protein-coupled receptor transactivation of the EGFR signaling pathway (5). Moreover, unlike iRhom2 KO mice, iRhom1 KO mice have a more severe phenotype and survive for about 6 wk (9).
In humans, dominant mutations in the N terminus of the RHBDF2 gene are associated with hyperkeratosis and esophageal cancer (11, 42) . Although the mechanisms underlying the pathogenesis of hyperkeratosis and cancer are unclear, analyses of skin biopsies of patients suggest constitutive EGFR activation. Specifically, EGFR levels were shown to be significantly lower in tylotic keratinocytes compared with control keratinocytes, implicating excessive or prolonged activation-induced downregulation of EGFR (11) . Interestingly, because the RHBDF2 mutations described to date arose in the N terminus, dominant mutations in the N terminus of iRhom2 could trigger esophageal cancer via an EGFR-dependent signaling event. In the present study, we find that N-terminal-truncated iRhom2 promotes increased AREG production independent of ADAM17 activity, and thereby induces EGFR activation. In particular, the phenotype of Apc Min/+ Rhbdf2 +/cub mice recapitulates the increased susceptibility to epithelial cancers seen in patients with dominant RHBDF2 mutations (11, 42) . However, Rhbdf2 cub/cub mice did not spontaneously develop tumors, suggesting that the Rhbdf2 cub mutation might not drive cancer development but, instead, might promote tumor growth and progression by creating a conducive environment.
Materials and Methods
Full details are available in SI Materials and Methods.
Mice were obtained, bred, and maintained under modified barrier conditions at The Jackson Laboratory. All genotypes, including cub and Mcub, were maintained on the C57BL/6J (B6) genetic background. To generate Working model for our study shows that WT iRhom2 is a short-lived protein, whereas loss of its N terminus or mutations in its N-terminal domain, including those that underlie epithelial cancers, increase its protein stability. Increased protein stability, in turn, augments the secretion of selective EGF family ligands, including AREG. Inhibition of ADAM17 has no effect on AREG secretion, whereas loss of amino acids H366, Q426, C432, and H475 in the peptidase domain of iRhom2 abrogates AREG secretion. Enhanced secretion of AREG leads to hyperactivation of EGFR signaling, and thereby increased cell proliferation and migration. ER, endoplasmic reticulum; ERAD, endoplasmic reticulum associated degradation.
